Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * VELOCITY PHARMACEUTICAL HOLDINGS LLC	2. Date of Event Requiring Statement (MM/DD/YYYY) 7/12/2019	3. Issuer Name and Ticker or Trading Symbol Altimmune, Inc. [ALT]
(Last)        (First)        (Middle) 400 OYSTER BLVD., SUITE 202	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          ___X___ 10% Owner _____ Officer (give title below)        _____ Other (specify below)
(Street) SOUTH SAN FRANCISCO, CA 94080       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1887250 (1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

(1)

The shares are directly held by Velocity Pharmaceutical Holdings LLC ("VPH"). Velocity Pharma Management, LLC ("VPM") is the manager of VPH. David J. Collier and James F. Watson are the managing members of VPM, and as such may be deemed to hold shared voting and dispositive power over the shares held by VPH. Mr. Collier and Mr. Watson disclaim beneficial ownership of the shares held by VPH except to the extent of their pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
VELOCITY PHARMACEUTICAL HOLDINGS LLC 400 OYSTER BLVD. SUITE 202 SOUTH SAN FRANCISCO, CA 94080		X
Collier David J C/O VELOCITY PHARMA MANAGEMENT, LLC 400 OYSTER BLVD.. SUITE 202 SOUTH SAN FRANCISCO, CA 94080		X
Watson James F C/O VELOCITY PHARMA MANAGEMENT, LLC 400 OYSTER BLVD.. SUITE 202 SOUTH SAN FRANCISCO, CA 94080		X
Velocity Pharma Management, LLC 400 OYSTER BLVD. SUITE 202 SOUTH SAN FRANCISCO, CA 94080		X

Signatures
By: /s/ David J. Collier, as a Reporting Owner and in his capacity as managing member of Velocity Pharma Management, LLC, the manager of Velocity Pharmaceutical Holdings LLC, and by power of attorney on behalf of James F. Watson		2/14/2020
**Signature of Reporting Person		Date